Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Finished Goods (2023 - 2025)

Iovance Biotherapeutics has reported Finished Goods over the past 3 years, most recently at $15.5 million for Q1 2025.

  • Quarterly results put Finished Goods at $15.5 million for Q1 2025, up 153.3% from a year ago — trailing twelve months through Mar 2025 was $15.5 million (up 153.3% YoY), and the annual figure for FY2024 was $15.0 million, up 224.72%.
  • Finished Goods for Q1 2025 was $15.5 million at Iovance Biotherapeutics, up from $15.0 million in the prior quarter.
  • Over the last five years, Finished Goods for IOVA hit a ceiling of $15.5 million in Q1 2025 and a floor of $1.1 million in Q2 2023.
  • Median Finished Goods over the past 3 years was $5.5 million (2023), compared with a mean of $7.9 million.
  • Biggest five-year swings in Finished Goods: skyrocketed 224.72% in 2024 and later surged 153.3% in 2025.
  • Iovance Biotherapeutics' Finished Goods stood at $4.6 million in 2023, then skyrocketed by 224.72% to $15.0 million in 2024, then rose by 3.55% to $15.5 million in 2025.
  • The last three reported values for Finished Goods were $15.5 million (Q1 2025), $15.0 million (Q4 2024), and $6.1 million (Q1 2024) per Business Quant data.